This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock CPSR vs. MOR, GMTX, CALT, ZYME, SBTX, MBX, AVTE, NLTX, CYBN, and BIOAShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), and BioAge Labs (BIOA). Capstar Special Purpose Acquisition vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs MorphoSys (NASDAQ:MOR) and Capstar Special Purpose Acquisition (NYSE:CPSR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations. Which has higher valuation and earnings, MOR or CPSR? Capstar Special Purpose Acquisition has lower revenue, but higher earnings than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Capstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/A Does the media favor MOR or CPSR? In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Capstar Special Purpose Acquisition'saverage media sentiment score. Company Overall Sentiment MorphoSys Neutral Capstar Special Purpose Acquisition Neutral Do insiders & institutionals believe in MOR or CPSR? 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 64.9% of Capstar Special Purpose Acquisition shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is MOR or CPSR more profitable? Capstar Special Purpose Acquisition has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Capstar Special Purpose Acquisition's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Capstar Special Purpose Acquisition N/A N/A N/A Which has more risk and volatility, MOR or CPSR? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Capstar Special Purpose Acquisition has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. SummaryCapstar Special Purpose Acquisition beats MorphoSys on 5 of the 8 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$848.86M$878.12M$5.77B$21.38BDividend YieldN/A4.84%6.66%3.49%P/E RatioN/A1.1283.0529.02Price / SalesN/A26.89527.2348.80Price / CashN/A19.5625.7018.29Price / Book-20.856.5511.005.30Net Income-$15.30M-$5.07M$3.28B$997.87M Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$24.60-0.1%N/A+277.1%$848.86MN/A0.002MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.41-1.6%N/A+17.4%$2.57BN/A-59.4130CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.2941 of 5 stars$14.85+0.1%$21.43+44.3%+19.4%$1.11B$122.87M-9.81460News CoveragePositive NewsGap DownSBTXSilverback TherapeuticsN/A$13.51+0.1%N/A-10.5%$487.14MN/A-5.5883High Trading VolumeMBXMBX Biosciences2.316 of 5 stars$14.46-6.0%$37.63+160.3%N/A$482.71MN/A-3.1636AVTEAerovate TherapeuticsN/A$8.03+1.6%N/A-88.3%$232.75MN/A-2.6920News CoveragePositive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.98-0.1%N/A-50.6%$187.77MN/A-6.4290CYBNCybin1.8749 of 5 stars$7.83+5.0%$85.00+986.3%N/A$183.53MN/A-1.7850News CoverageGap DownBIOABioAge LabsN/A$4.74+2.8%N/AN/A$169.93MN/A0.00N/A Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors Cybin Competitors BioAge Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CPSR Stock Alerts